Developer docs
API playgroundTry for free, no card

Search company profiles

Avid Radiopharmaceuticals

Full company profile

uuid0009ki9

Namestring
Avid Radiopharmaceuticals
Legal namestring
Avid Radiopharmaceuticals, Inc
Websiteurl
avidrp.com
Company typeenum
Private
Founded yearint
2005
Short descriptiontext

Avid Radiopharmaceuticals, founded in 2005 and based in Philadelphia, is a wholly-owned subsidiary of Eli Lilly that develops proprietary molecular imaging agents for detecting and monitoring chronic neurological diseases, serving healthcare providers, pharmaceutical companies, and diagnostic laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
molecular imaging agents, diagnostic radiopharmaceuticals, neurological disease diagnostics, PET imaging tracers, Alzheimer's disease imaging
Industry1 code
1Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
CodeHLAIAGAAPrimaryYes
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Diagnostic Radiopharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Avid Radiopharmaceuticals develops molecular imaging agents used to detect and monitor chronic human diseases, with a specialization in diagnostic solutions for neurological conditions such as Alzheimer's disease. The company operates as a wholly-owned subsidiary of Eli Lilly and Company, leveraging Lilly's biotechnology, chemistry, and genetic medicine platforms to deliver diagnostic products that improve global health outcomes and accelerate the development of new medicines.

Differentiator
Functional benefit
Problem solved
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Eli Lilly and Company
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Avid Radiopharmaceuticals is a wholly-owned subsidiary of Eli Lilly and Company. Avid's mission to discover, develop, and deliver diagnostic solutions that improve global health aligns with Lilly's pursuit of breakthrough science. As part of Lilly's subsidiary network, Avid benefits from Lilly's resources, technology platforms, and global reach in biotechnology, chemistry, and genetic medicine to accelerate the development of new medicines.

Peers10 records
1GE HealthCare
TypeDirect peer
Description

GE HealthCare developed Vizamyl (flutemetamol), an FDA-approved amyloid PET tracer directly competing with Avid's Amyvid in Alzheimer's imaging. The two companies lead the commercial PET amyloid diagnostic market.

2Life Molecular Imaging
TypeDirect peer
Description

Life Molecular Imaging (a Piramal company) developed and commercializes Neuraceq (florbetaben), another FDA-approved amyloid PET tracer for Alzheimer's diagnosis, directly competing with Avid's Amyvid.

3Cerveau Technologies
TypeDirect peer
Description

Cerveau develops tau PET imaging agents (MK-6240) for neurodegenerative disease. Acquired by Lilly in 2023, it is now a sibling Avid subsidiary and directly comparable as a CNS-focused radiopharmaceutical developer.

4C2N Diagnostics
TypeEmerging player
Description

C2N Diagnostics offers the PrecivityAD blood test for amyloid detection, representing an emerging non-PET diagnostic modality that competes with Avid's imaging-based franchise in Alzheimer's.

5Fujirebio (H.U. Group Holdings)
TypeEmerging player
Description

Fujirebio received FDA breakthrough designation and approval for Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio assays, offering a blood-based alternative to PET imaging for Alzheimer's diagnosis that could compete with Avid.

6Roche Diagnostics
TypeBroad incumbent
Description

Roche's Elecsys CSF immunoassays for Alzheimer's biomarkers (pTau181, Aβ42) are a well-established diagnostic alternative to PET imaging and represent a broad incumbent diagnostic competitor to Avid's neurological franchise.

7Quanterix
TypeEmerging player
Description

Quanterix's Simoa single-molecule array platform powers ultra-sensitive blood-based biomarker detection for neurodegenerative disease, offering an emerging scalable alternative to Avid's PET imaging agents.

8Lantheus Holdings
TypeDirect peer
Description

Lantheus is a leading radiopharmaceutical company with a portfolio including PyL (PSMA PET agent) and Alzheimer imaging pipeline assets. Its radiopharmaceutical development and commercialization capabilities make it a direct peer to Avid.

9Bayer (Curium / Telix Pharmaceuticals partnership)
TypeBroad incumbent
Description

Bayer has significant radiopharmaceutical investments including Xofigo and pipeline agents, and through its broader pharmaceutical franchise competes with Lilly/Avid in adjacent imaging and therapeutic radiopharma markets.

10Eisai
TypeOthers
Description

Eisai co-develops Leqembi (lecanemab) with Biogen, the leading competing Alzheimer's therapeutic to Lilly's Kisunla. As a therapeutic competitor, Eisai indirectly shapes demand for Avid's companion diagnostics in Alzheimer's.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Avid Radiopharmaceuticals

Diagnostic Radiopharmaceuticalsavidrp.com

Avid Radiopharmaceuticals, founded in 2005 and based in Philadelphia, is a wholly-owned subsidiary of Eli Lilly that develops proprietary molecular imaging agents for detecting and monitoring chronic neurological diseases, serving healthcare providers, pharmaceutical companies, and diagnostic laboratories.

Avid Radiopharmaceuticals firmographics

Firmographics
Name
Avid Radiopharmaceuticals
Legal name
Avid Radiopharmaceuticals, Inc
Website
https://avidrp.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Avid Radiopharmaceuticals, founded in 2005 and based in Philadelphia, is a wholly-owned subsidiary of Eli Lilly that develops proprietary molecular imaging agents for detecting and monitoring chronic neurological diseases, serving healthcare providers, pharmaceutical companies, and diagnostic laboratories.
Ownership category
akta.pro rank

Avid Radiopharmaceuticals industry classification

Industry
Product category
Diagnostic Radiopharmaceuticals
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA)

Keywords

  • Molecular imaging agents
  • Diagnostic radiopharmaceuticals
  • Neurological disease diagnostics
  • PET imaging tracers
  • Alzheimer's disease imaging

Where Avid Radiopharmaceuticals is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Markets served

Avid Radiopharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Avid Radiopharmaceuticals product offering

Product offering

Core offering

Avid Radiopharmaceuticals develops molecular imaging agents used to detect and monitor chronic human diseases, with a specialization in diagnostic solutions for neurological conditions such as Alzheimer's disease. The company operates as a wholly-owned subsidiary of Eli Lilly and Company, leveraging Lilly's biotechnology, chemistry, and genetic medicine platforms to deliver diagnostic products that improve global health outcomes and accelerate the development of new medicines.

Differentiator

Problem solved

Functional benefit

Companies that use Avid Radiopharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Avid Radiopharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Avid Radiopharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Eli Lilly and CompanycoreStrategic or Co-development PartnerAvid Radiopharmaceuticals is a wholly-owned subsidiary of Eli Lilly and Company. Avid's mission to discover, develop, and deliver diagnostic solutions that improve global health aligns with Lilly's pursuit of breakthrough science. As part of Lilly's subsidiary network, Avid benefits from Lilly's resources, technology platforms, and global reach in biotechnology, chemistry, and genetic medicine to accelerate the development of new medicines.

Scale indicators2 records

Avid Radiopharmaceuticals competitors and assessment

Company assessment

Direct peers

  • GE HealthCare: GE HealthCare developed Vizamyl (flutemetamol), an FDA-approved amyloid PET tracer directly competing with Avid's Amyvid in Alzheimer's imaging. The two companies lead the commercial PET amyloid diagnostic market.
  • Life Molecular Imaging: Life Molecular Imaging (a Piramal company) developed and commercializes Neuraceq (florbetaben), another FDA-approved amyloid PET tracer for Alzheimer's diagnosis, directly competing with Avid's Amyvid.
  • Cerveau Technologies: Cerveau develops tau PET imaging agents (MK-6240) for neurodegenerative disease. Acquired by Lilly in 2023, it is now a sibling Avid subsidiary and directly comparable as a CNS-focused radiopharmaceutical developer.
  • Lantheus Holdings: Lantheus is a leading radiopharmaceutical company with a portfolio including PyL (PSMA PET agent) and Alzheimer imaging pipeline assets. Its radiopharmaceutical development and commercialization capabilities make it a direct peer to Avid.

Emerging players

  • C2N Diagnostics: C2N Diagnostics offers the PrecivityAD blood test for amyloid detection, representing an emerging non-PET diagnostic modality that competes with Avid's imaging-based franchise in Alzheimer's.
  • Fujirebio (H.U. Group Holdings): Fujirebio received FDA breakthrough designation and approval for Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio assays, offering a blood-based alternative to PET imaging for Alzheimer's diagnosis that could compete with Avid.
  • Quanterix: Quanterix's Simoa single-molecule array platform powers ultra-sensitive blood-based biomarker detection for neurodegenerative disease, offering an emerging scalable alternative to Avid's PET imaging agents.

Broad incumbents

  • Roche Diagnostics: Roche's Elecsys CSF immunoassays for Alzheimer's biomarkers (pTau181, Aβ42) are a well-established diagnostic alternative to PET imaging and represent a broad incumbent diagnostic competitor to Avid's neurological franchise.
  • Bayer (Curium / Telix Pharmaceuticals partnership): Bayer has significant radiopharmaceutical investments including Xofigo and pipeline agents, and through its broader pharmaceutical franchise competes with Lilly/Avid in adjacent imaging and therapeutic radiopharma markets.

Others

  • Eisai: Eisai co-develops Leqembi (lecanemab) with Biogen, the leading competing Alzheimer's therapeutic to Lilly's Kisunla. As a therapeutic competitor, Eisai indirectly shapes demand for Avid's companion diagnostics in Alzheimer's.

Market position

Customer concentration

Avid Radiopharmaceuticals social profiles

Digital presence

Avid Radiopharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Avid Radiopharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Avid Radiopharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Avid Radiopharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avid Radiopharmaceuticals

What does Avid Radiopharmaceuticals do?

Avid Radiopharmaceuticals develops molecular imaging agents used to detect and monitor chronic human diseases, with a specialization in diagnostic solutions for neurological conditions such as Alzheimer's disease. The company operates as a wholly-owned subsidiary of Eli Lilly and Company, leveraging Lilly's biotechnology, chemistry, and genetic medicine platforms to deliver diagnostic products that improve global health outcomes and accelerate the development of new medicines.

Is Avid Radiopharmaceuticals a public or private company?

Avid Radiopharmaceuticals is a private company. It is classified as corporate owned and is currently operating.

When was Avid Radiopharmaceuticals founded?

Avid Radiopharmaceuticals was founded in 2005. It employs 51 to 100 people.

Where is Avid Radiopharmaceuticals based?

Avid Radiopharmaceuticals is headquartered in Philadelphia, United States, in the North America region.

Who are Avid Radiopharmaceuticals's main competitors?

Direct peers on record are GE HealthCare, Life Molecular Imaging, Cerveau Technologies and Lantheus Holdings. Emerging players are C2N Diagnostics, Fujirebio (H.U. Group Holdings) and Quanterix. Broad incumbents are Roche Diagnostics and Bayer (Curium / Telix Pharmaceuticals partnership). Eisai is listed as an others.

Does Avid Radiopharmaceuticals have an API?

No public API is recorded for Avid Radiopharmaceuticals.

What industry is Avid Radiopharmaceuticals in?

Avid Radiopharmaceuticals's product category is Diagnostic Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PhirdaEli Lilly's 10-Year Comeback: 'Failing Fast' is the Biggest SuccessEli Lilly's market value surpassed $1 trillion after a decade of internal R&D success, driven by Donanemab and Tirzepatide. CEO Dave Ricks credited 'failing fast' and a shift from commercial pull to scientific push, with 8 of 13 blockbuster drugs from 2010-2020 independently developed. The company cut preclinical time to 2.5 years and approval time to 5.9 years.PR NewswireLilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's DiseaseEli Lilly and Company's wholly owned subsidiary Avid Radiopharmaceuticals received U.S. FDA approval for TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent for PET brain imaging to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment being evaluated for Alzheimer's disease. TAUVID is the first and only approved diagnostic agent to image tau NFTs in the brain, complementing the existing AMYVID product for beta-amyloid plaque imaging. The company stated that availability will initially be limited and will expand in response to commercial demand and payor reimbursement.PR NewswireFDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer's DiseaseThe U.S. Food and Drug Administration approved Tauvid (flortaucipir F18), the first drug to image tau pathology in the brain for patients with cognitive impairment being evaluated for Alzheimer's disease. Tauvid is a radioactive diagnostic agent for PET imaging that binds to tau neurofibrillary tangles, one of the two hallmarks of Alzheimer's disease, which previously could only be definitively diagnosed post-mortem. The FDA granted approval to Avid Radiopharmaceuticals, Inc., with clinical studies showing high reader agreement (0.87 across 241 patients) and a high probability of correctly evaluating patients with and without tau pathology.PR NewswireNew Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's DiseaseEli Lilly and Company announced results from two analyses of a phase 2 study using its tau imaging agent flortaucipir, presented at the Alzheimer's Association International Conference 2016 in Toronto. The first analysis found that tau signal in beta-amyloid positive patients increased significantly over 18 months, while the second showed a correlation between tau location in the brain and progression of cognitive decline. Avid Radiopharmaceuticals, Lilly's wholly owned subsidiary, conducted the research with 217 subjects across multiple diagnostic groups.